Dr. Steven Gore on Potential Negative Effects of Further Research into Azanucleoside Combinations

October 28, 2015
Steven Gore, MD

Steven D. Gore, MD, director of Hematologic Malignancies at Yale Cancer Center, talks about the risk of constantly testing azanucleoside combinations without significant results. Gore says that testing azanucleoside combinations that are not well planned may cause the medical community to overlook an effective combination due to fatigue of constant testing.

Steven D. Gore, MD, director of Hematologic Malignancies at Yale Cancer Center, talks about the risk of constantly testing azanucleoside combinations without significant results. Gore says that testing azanucleoside combinations that are not well planned may cause the medical community to overlook an effective combination due to fatigue of constant testing.

Gore cites the constant study, and eventual tiring by the medical community, of an azanucleoside combination for the reversal of multi drug phenotype, MDR1.